Gavriatopoulou M, García-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129(4):456-459.

doi:10.1182/blood.2022015380

On page 456, in the last line of the abstract and line 4 of “Study design,” the clinical trial registration number (#NCT00981708) should be #NCT00832234. The error has been corrected in the online version of the article.

2022

Sign in via your Institution

Gavriatopoulou M, García-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129(4):456-459.

Cited By

Email alerts

ASH Publications

American Society of Hematology

Gavriatopoulou M, García-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129(4):456-459.

This feature is available to Subscribers Only

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only